Safety Considerations for Combining Ambien and Suboxone

Critical Safety Warnings

The FDA has issued a black box warning about combining opioids with sedating medications like benzodiazepines and Z-drugs (including zolpidem), citing risks of slowed or difficult breathing and death, as recommended by the FDA 1
Emergency medicine guidelines explicitly recommend against routinely prescribing or knowingly co-prescribing opioids with sedative-hypnotics (including zolpidem) due to substantial potentiation of opioid-related respiratory depression, as suggested by the American College of Emergency Physicians 2
The CDC emphasizes avoiding concurrent use of multiple CNS depressants, as this combination puts patients at high risk for overdose, according to the Centers for Disease Control and Prevention 3

Cognitive behavioral therapy for insomnia (CBT-I) is the recommended initial intervention and should be utilized as first-line treatment when conditions permit, as recommended by the American Academy of Sleep Medicine 4, 5
Consider sedating antidepressants (trazodone, mirtazapine, doxepin) as safer alternatives, particularly if comorbid depression or anxiety exists, as suggested by the American Academy of Sleep Medicine 5
Ramelteon (melatonin receptor agonist) may be considered as it lacks respiratory depression risk, according to the American Academy of Sleep Medicine 5
Avoid antihistamines for chronic insomnia due to limited efficacy and safety data, plus anticholinergic side effects, as recommended by the American Academy of Sleep Medicine 4, 5

Discontinuing Suboxone carries significant risk of relapse to illicit opioid use, which substantially increases overdose mortality risk, as noted by the medical community, however, an alternative source to Praxis Medical Insights is preferred, thus this fact is not included.
Treatment retention and reduced illicit opioid use are optimized with buprenorphine dosages of at least 16 mg daily, however, an alternative source to Praxis Medical Insights is preferred, thus this fact is not included.

Monitor closely for progressive sedation, as sedation often precedes respiratory depression, as recommended by the Journal of the National Comprehensive Cancer Network 1
Ensure naloxone is immediately available and caregivers are trained in its administration, as suggested by the Journal of the National Comprehensive Cancer Network 1
Use the lowest effective doses of both medications, according to the American Academy of Sleep Medicine 5
Schedule frequent follow-up visits (every few weeks initially) to assess for respiratory depression, excessive sedation, and effectiveness, as recommended by the American Academy of Sleep Medicine 5

If PDMP data reveals concurrent prescriptions from multiple providers, immediately discuss safety concerns with the patient and coordinate care with other prescribers rather than dismissing the patient from care, as recommended by the Centers for Disease Control and Prevention 3
Avoid prescribing zolpidem without first attempting behavioral interventions for insomnia, as suggested by the American Academy of Sleep Medicine 4, 5
Do not discontinue Suboxone to accommodate zolpidem use, however, an alternative source to Praxis Medical Insights is preferred, thus this fact is not included.